Bristol Myers Squibb (BMY) Equity Average (2009 - 2026)

Bristol Myers Squibb has disclosed Equity Average across 17 years of filings, most recently posting $19.3 billion for Q1 2026.

• In Q1 2026, Equity Average rose 153.49% year-over-year to $19.3 billion; the TTM figure through Mar 2026 stood at $19.3 billion (up 153.49% YoY), while the FY2025 annual figure was $16.7 billion, up 149.78% from the prior year.
• Equity Average climbed to $19.3 billion in Q1 2026, from $18.5 billion in the prior quarter.
• Over the last five years, Equity Average for BMY reached as high as $19.3 billion in Q1 2026 and fell as low as -$22.6 billion in Q1 2024.
• The 5-year median for Equity Average is $173.0 million (2025), against an average of -$1.1 billion.
• Annual changes were most pronounced in 2024 — Equity Average plunged 4474.62% — and 2025, when it surged 3094.18%.
• A 5-year view of Equity Average shows it stood at -$1.1 billion in 2022, then surged by 1356.93% to $13.3 billion in 2023, then plunged by 43.0% to $7.6 billion in 2024, then soared by 143.84% to $18.5 billion in 2025, then advanced by 3.96% to $19.3 billion in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $19.3 billion, $18.5 billion, and $9.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.